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Abstract
Background: Increased hepatic iron is assumed to potentiate progression towards liver fibrosis
in chronic hepatitis C virus (HCV) infection. In this study we have evaluated the potentiating effect
of marked hepatic iron overload and chronic HCV infection on hepatic fibrosis in thalassemic
patients.
Methods: Liver biopsies of one group of patients with beta thalassemia major and chronic HCV
infection (group 1) was compared with two groups of patients (groups 2&3) with either chronic
HCV infection or thalassemia major, respectively (20 patients in each group). Necroinflammation,
fibrosis, and iron overload were graded and compared.
Results: Stage of fibrosis in group 1 patients was significantly higher than the other two groups (p
< 0.05). Necroinflammatory grade was significantly lower, but iron score was significantly higher in
thalassemic patients (group 3) in comparison to groups 1 and 2 (p < 0.05).
Conclusion:  Our results indicate that marked liver iron overload and HCV infection in
thalassemic patients have potentiating effect on hepatic fibrogenesis.
Background
Thalassemia major is an inherited disorder particularly
common in people of Mediterranean, African, and South-
east Asian ancestry. It is characterized by decreased pro-
duction of beta chain of hemoglobin. Clinical features
result from anemia, markedly expanded marrow space,
and transfusional and absorptive iron overload. In these
patients iron overload is often inevitable, especially when
iron chelating agents are not used properly [1]. Hepatic
iron overload leads to different degrees of liver fibrosis,
the severity of which is closely correlated with the severity
of liver iron overload [2]. The pattern of iron deposition
seen in the initial stages of thalassemia major is preferen-
tially sinusoidal with a more or less diffuse distribution
within the acinus. With significant loading, hepatocytes,
bile duct epithelia, and fibrous tissue of portal tracts or
septa will also show iron deposition [3].
Published: 12 August 2004
BMC Gastroenterology 2004, 4:17 doi:10.1186/1471-230X-4-17
Received: 24 April 2004
Accepted: 12 August 2004
This article is available from: http://www.biomedcentral.com/1471-230X/4/17
© 2004 Ardalan et al; licensee BioMed Central Ltd. 
This is an open-access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.BMC Gastroenterology 2004, 4:17 http://www.biomedcentral.com/1471-230X/4/17
Page 2 of 4
(page number not for citation purposes)
HCV is responsible for 80–90% of post-transfusional
cases of hepatitis in patients who have received blood
transfusion(s) prior to the introduction of routine blood
products screening in 1990 [4]. More than 75% of HCV
infections become chronic and up to 20–30% progress to
cirrhosis [3-5].
Increased hepatic iron may potentiate progression
towards liver fibrosis in chronic HCV infection, and may
contribute to poor response to interferon therapy [3,6,7].
Acceleration of hepatic fibrosis in patients with combined
hereditary hemochromatosis (HH) and chronic hepatitis
C infection has also been shown [7]. Nevertheless, the
pattern of iron deposition in HH is initially hepatocellular
and different from that of thalassemia major. In this study
we have evaluated the potentiating effect of marked
hepatic iron overload and chronic HCV infection on
hepatic fibrosis in thalassemic patients. To the best of our
knowledge this synergic effect has been studied just in
another study on bone marrow transplanted thalassemic
patients [8].
Methods
A retrospective cross-sectional study was performed on
sixty patients in three different groups as outlined below:
Group 1: Twenty patients (10 males, 10 females) with the
diagnosis of thalassemia major and chronic HCV infec-
tion (BTM/CHI). The only risk factor of HCV infection in
these patients was blood transfusion before 1990.
Group 2: Twenty patients (13 males, 7 females) with
chronic HCV infection (CHI). The route of infection and
the duration of disease were not known in most of the
patients.
Group 3: Twenty patients (10 males, 10 females) with tha-
lassemia major.
Thalassemia major was diagnosed by appropriate clinical
and laboratory findings, and confirmed by hemoglobin
electrophoresis. All the thalassemic patients had received
multiple blood transfusions since childhood, and only
those with at least moderate hepatic iron overload (2/4
based on Marx and Sindram hepatic iron scoring [9]) were
included.
CHI was confirmed by positive anti-HCV (enzyme-linked
immunosorbant assay), a positive HCV RNA by polymer-
ase chain reaction and appropriate findings on liver
biopsy.
Patients with history of alcohol intake, smoking, positive
HIV serology, positive HBs antigen or HBc antibody, and
other liver diseases (e.g., autoimmune hepatitis, drug
hepatotoxicity, Wilson's disease, alpha-1 antitrypsin defi-
ciency, hereditary hemochromatosis) were excluded from
all the three groups.
All of the patients whose liver biopsies were submitted to
the Central Pathology Department of Imam Khomeini
Hospital (a Terhan University of Medical Sciences affili-
ated hospital) between April 2001 and January 2004 were
retrieved. During this period, there were only 20 tha-
lassemic patients with moderate to marked hepatic iron
overload, so all of them were included in our study. Since
the sex and age distribution of patients with thalassemia
major and BTM/CHI were relatively the same, 20 patients
with BTM/CHI and at least moderate hepatic iron over-
load were randomly selected from all the patients with
this diagnosis. On the other hand, patients with CHI had
a considerably higher age, so to match the age of the
patients, we selected 20 of the youngest patients.
For all the sixty patients, we had hematoxylin and eosin,
Masson's trichrome and Perls' Prussian blue stains. All the
slides were reviewed by a single pathologist (FAA) who
was blind to the diagnoses. The necroinflammation,
fibrosis, and iron deposition were scored using modified
Hepatitis Activity Index (HAI) grading, modified HAI
staging, and Marx/Sindram hepatic iron scoring systems,
respectively [9,10]. Presence or absence of macrovesicular
steatosis was also assessed.
Statistical analysis
The results are presented as mean value +/- standard devi-
ation (for age), median and range values (for modified
HAI grade, stage, and iron score) and percentages (for
steatosis). Group comparisons were made using the two-
tailed independent Student's t-test for age and two-sided
Fisher's exact or Chi2 tests for other variables with p < 0.05
considered to be significant.
For each patient with BTM/CHI (doubly exposed cases),
there were two different unexposed cases, i.e. thalassemic
cases (unexposed to HCV) and CHI cases (unexposed to
iron overload). Considering "disease" as higher stages of
fibrosis (modified HAI stage ≥ 3), our guesstimate of the
expected frequency of disease in unexposed and exposed
patients were about 25% and 75%, respectively. So the
sample size was calculated as about 20 patients for each
group with confidence level of 95% and power of 80%.
Results and Discussion
The results of the study are summarized in table 1. This
study supports the synergic effects of CHI and marked
hepatic iron deposition in thalassemic patients on liver
fibrosis. The patients with BTM/CHI had higher stages of
liver fibrosis in comparison to patients with either CHI or
thalassemia major alone. The patients with BTM/CHI hadBMC Gastroenterology 2004, 4:17 http://www.biomedcentral.com/1471-230X/4/17
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higher stages of fibrosis despite lower scores for iron over-
load in comparison to thalassemic patients. The potenti-
ating effect of hepatic iron overload and CHI has been
shown in other studies [7,8,11,12]. The cause of iron over-
load in the majority of studies has been hereditary hemo-
chromatosis or HFE mutations.
Angelucci et al showed for the first time the role of iron
overload and HCV positivity as independent risk factors
for hepatic fibrosis progression in thalassemic patients
following successful bone marrow transplantation [8].
The Angelucci's study has a few advantages over our study:
firstly, serial liver biopsies have been studied and the rate
of liver fibrosis progression assessed. Secondly, hepatic
iron concentration was used instead of scoring of staina-
ble iron. Thirdly, two pathologists reviewed the slides
independently. And finally, the sample size was much
larger, but that study does not show whether the rate of
hepatic fibrosis progression in BTM/CHI patients is
greater than patients with only CHI.
The potentiating effect of iron overload and HCV infec-
tion can be explained by the fact that both these agents
produce oxidative stress in the liver [7,13]. In our study
the grade of necroinflammation in BTM/CHI patients was
not significantly different from CHI patients. Other stud-
ies have shown the same results [3,7].
Limitations of our study were that it was a retrospective
study with limited number of patients in each group. The
duration of HCV infection and genotype of virus were not
known in our patients. The routes of infection in most of
the CHI patients were not known and where probably dif-
ferent from our thalassemic patients. The age of our CHI
group was significantly higher than the other two groups.
Since older age at the time of infection is considered to be
a risk factor for progression of chronic hepatitis C, the
stage of fibrosis should have been higher in our CHI
patients than BTM/CHI patients if iron had not had any
potentiating effect on liver fibrosis. Our study was per-
formed on thalassemic patients with moderate to severe
liver iron deposition. At these stages of iron overload, the
pattern of hepatic iron deposition in HH and thalassemic
patients are nearly the same. So this study does not reveal
the effect of only sinusoidal iron deposition on progres-
sion of fibrosis in HCV infected thalassemic patients.
Conclusions
Our results show that moderate to severe liver iron over-
load and chronic HCV infection in thalassemic patients
have potentiating effect on hepatic fibrogenesis. So the
proper use of chelating agents in HCV-infected tha-
lassemic patients seems to be of great importance in
delaying progression of the liver disease. The presence of
liver siderosis has been shown to be related to poor
response to interferon alpha (IFN) in non-thalassemic
patients [3,6,7,12,14,15]; hence one can expect a poor
response to IFN therapy because of transfusion related
siderosis in thalassemic patients. However studies have
shown that in thalassemic subjects, there is a promising
response to IFN therapy (as high as 50% sustained
response in some series) [16,17]. Perhaps in these patients
(BTM/CHI), the therapeutic protocol for chronic HCV
infection should differ from those without significant iron
overload, but further studies are needed to confirm or
refute these suggestions.
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Table 1: Demographic and histopathologic findings in the three groups
Group 1 Group 2 Group 3 P value
Group 1 vs. 2 Group 1 vs. 3
Age(years)* 21.55+/-4.74 29.7+/-9.16 18.7+/-4.45 0.001 0.057
Sex (M/F) 10/10 13/7 10/10 0.33 1
Modified Stage‡ 3 (1–6) 2 (0–6) 2 (1–4) 0.02 0.01
Modified HAI grade‡ 5 (1–8) 6 (2–11) 2 (0–6) 0.36 0.001
Periportal inflammation‡ 1.5 (0–3) 2 (0–4) 0 (0–2) 0.77 0.004
Confluent Necrosis‡ 0 (0–1) 0 (0–2) 0 (0–1) 0.13 0.091
Focal Necrosis‡ 1 (0–2) 2 (1–2) 1 (0–2) 0.10 0.45
Portal Inflammation‡ 2 (0–3) 2 (1–4) 1 (0–2) 0.87 0.002
Iron Score‡ 3 (2–4) 0 (0–1) 4 (2–4) 0.000 0.024
Steatosis (%) 10 20 0 0.66 0.48
* mean+/-standard deviation ‡Median (minimum-maximum) Group 1: Patients with beta thalassemia major and chronic HCV infection Group 2: 
Patients with chronic HCV infection Group 3: Patients with beta thalassemia majorPublish with BioMed Central    and   every 
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